Identification of the bovine γ-aminobutyric acid type A receptor α subunit residues photolabeled by the imidazobenzodiazepine [3H]Ro15-4513

被引:44
作者
Sawyer, GW
Chiara, DC
Olsen, RW [1 ]
Cohen, JB
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmaocl, Los Angeles, CA 90095 USA
[2] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA
关键词
D O I
10.1074/jbc.M209281200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ligands binding to the benzodiazepine-binding site in gamma-aminobutyric acid type A (GABA(A)) receptors may allosterically modulate function. Depending upon the ligand, the coupling can either be positive (flunitrazepam), negative (Ro15-4513), or neutral (flumazenil). Specific amino acid determinants of benzodiazepine binding affinity and/or allosteric coupling have been identified within GAEA(A) receptor alpha and gamma subunits that localize the binding site at the subunit interface. Previous photolabeling studies with [H-3]flunitrazepam identified a primary site of incorporation at alpha(1)His-102, whereas studies with [H-3]Ro15-4513 suggested incorporation into the a, subunit at unidentified amino acids C-terminal to alpha(1)His-102. To determine the site(s) of photoincorporation by Ro15-4513, we affinity-purified (similar to200-fold) GABAA receptor from detergent extracts of bovine cortex, photolabeled it with [H-3]Ro15-4513, and identified H-3-labeled amino acids by N-terminal sequence analysis of subunit fragments generated by sequential digestions with a panel of proteases. The patterns of 3 H release seen after each digestion of the labeled fragments determined the number of amino acids between the cleavage site and labeled residue, and the use of sequential proteolytic fragmentation identified patterns of cleavage sites unique to the different a subunits. Based upon this radiochemical sequence analysis, [H-3]Ro15-4513 was found to selectively label the homologous tyrosines alpha(1)Tyr-210, alpha(2)Tyr-209, and alpha(3)Tyr-234, in GABAA receptors containing those subunits. These results are discussed in terms of a homology model of the benzodiazepine-binding site based on the molluscan acetylcholine-binding protein structure.
引用
收藏
页码:50036 / 50045
页数:10
相关论文
共 51 条
[1]   Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acid(A) receptors [J].
Amin, J ;
BrooksKayal, A ;
Weiss, DS .
MOLECULAR PHARMACOLOGY, 1997, 51 (05) :833-841
[2]   Molecular and pharmacological characterization of native cortical gamma-aminobutyric acid(A) receptors containing both alpha(1) and alpha(3) subunits [J].
Araujo, F ;
Tan, S ;
Ruano, D ;
Schoemaker, H ;
Benavides, J ;
Vitorica, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (44) :27902-27911
[3]  
Barnard EA, 1998, PHARMACOL REV, V50, P291
[4]   Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors [J].
Brejc, K ;
van Dijk, WJ ;
Klaassen, RV ;
Schuurmans, M ;
van der Oost, J ;
Smit, AB ;
Sixma, TK .
NATURE, 2001, 411 (6835) :269-276
[5]   NEW PHOTOLABELING AND CROSS-LINKING METHODS [J].
BRUNNER, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :483-514
[6]   Residues at positions 206 and 209 of the alpha 1 subunit of gamma-aminobutyric acid(A) receptors influence affinities for benzodiazepine binding site ligands [J].
Buhr, A ;
Schaerer, MT ;
Baur, R ;
Sigel, E .
MOLECULAR PHARMACOLOGY, 1997, 52 (04) :676-682
[7]   Subtle changes in residue 77 of the gamma subunit of alpha 1 beta 2 gamma 2 GABA(A) receptors drastically alter the affinity for ligands of the benzodiazepine binding site [J].
Buhr, A ;
Baur, R ;
Sigel, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (18) :11799-11804
[8]  
Chang YC, 1996, J NEUROSCI, V16, P5415
[9]   Anxiety over GABAA receptor structure relieved by AChBP [J].
Cromer, BA ;
Morton, CJ ;
Parker, MW .
TRENDS IN BIOCHEMICAL SCIENCES, 2002, 27 (06) :280-287
[10]   Identification of domains in human recombinant GABA(A) receptors that are photoaffinity labelled by [H-3]flunitrazepam and [H-3]Ro15-4513 [J].
Davies, M ;
Martin, IL ;
Bateson, AN ;
Hadingham, KL ;
Whiting, PJ ;
Dunn, SMJ .
NEUROPHARMACOLOGY, 1996, 35 (9-10) :1199-1208